PECS and Parasternal Block for Breast Surgery (PARAST)

February 3, 2017 updated by: Erika Basso Ricci, Istituti Ospitalieri di Cremona

Observational Study to Evaluated Efficacy of Parasternal and PECS Blocks Association in Breast Surgery

Propose to evaluate efficacy of association between US guide parasternal block and pectorals nerves block (PECS) as anesthetic option for breast surgery (medial quadrantectomy and simple mastectomy).

All patients undergoing medial quadrantectomy and simple mastectomy in 6 months period will be observed.

All patients receive: US guide parasternal block at T4 and T6 space with 6ml of ropivacaine 0,75% and PECS type 2 block performed with 24ml of ropivacaine 0,75%.

During surgery patients receive light sedation with continuous infusion of propofol

Will be observed:

Additional local anesthetic infiltration from surgeon. Pain at rest and during movement quantified as Numerical Rating Scores (0-10) during the first 12 hours postoperatively.

Eventual side effects such as nausea/vomiting.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

32

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Cremona
      • Creom, Cremona, Italy, 26100
        • ASST Cremona

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Patients undergoing breast surgery

Description

Inclusion Criteria:

  • age> 18 years;
  • ASA score I - II - III;
  • undergoing elective medial quadrantectomy breast surgery;
  • undergoing elective mastectomy not reconstruction breast surgery;
  • signed informed consent;

Exclusion Criteria:

  • chronic therapy with opioids/ antidepressants;
  • urgent/emergent surgery;
  • postoperative transfer to the intensive care unit;
  • known allergy to any drug medication;
  • local skin infection;
  • epilepsy;
  • alcohol or drug abuse;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Local Anesthetic infiltration
Time Frame: intraoperatory period
Quantify amount of local anesthetic infiltration from surgeon to get perfect anesthesia
intraoperatory period
Convention in general anesthesia
Time Frame: preoperative period
Number of patients require general anestesia to proceed to surgery
preoperative period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain
Time Frame: 12 hours postoperatively
Rest and in mouvement pain as NRS scale
12 hours postoperatively
PONV
Time Frame: 12 hours postoperatively
Postoperative nausea/vomiting incidence
12 hours postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2016

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

February 1, 2017

Study Registration Dates

First Submitted

February 2, 2017

First Submitted That Met QC Criteria

February 3, 2017

First Posted (Estimate)

February 6, 2017

Study Record Updates

Last Update Posted (Estimate)

February 6, 2017

Last Update Submitted That Met QC Criteria

February 3, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • ANECR_01_17

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mastectomy

3
Subscribe